About the Alman Lab
The long-term goal of his work is to use this knowledge to identify improved therapeutic approaches to orthopaedic pathologic disorders. He makes extensive use of genetically modified mice to model human disease, and used this approach to identify new drug therapies for musculoskeletal tumors and to improve the outcome of related processes in cartilage, skin, and bone. As part of this work, Dr. Alman generated novel genetically modified mice to study tumors and reparative processes and is using these to develop new therapies. He also works on cellular heterogeneity in bone tumors, such as sarcomas, and how this relates to developmental processes. His lab identified a subpopulation of tumor initiating cells in musculoskeletal tumors, and found that this subpopulation of is responsible for sarcoma self-renewal. Another focus of the Alman Lab is to determine the regulation of mesenchymal cells in repair processes. Dr. Alman’s work on beta-catenin (ß-catenin) using transgenic mice was the first demonstration of the importance of this pathway in fracture repair. More recently, he used lineage-tracing studies to investigate the role of macrophage cells in skin and bone repair, and found a novel role for young hematopoietic cells in rejuvenating fracture repair. Dr. Alman is the principal investigator on several NIH grants; has more than 175 peer-reviewed publications in journals such as Lancet, Cell, and Nature Medicine; and has supervised over 30 graduate students and postdoctoral research trainees in his lab. He was recruited to Duke from Toronto’s Hospital for Sick Children in 2013.
Benjamin A. Alman, MD
Dr. Tomasa Barrientos De Renshaw
By Duke Medicine News and Communications Contact: Samiha Khanna Phone: 919-419-5069 Email: firstname.lastname@example.org https://www.dukehealth.org EMBARGOED FOR RELEASE until 12 p.m. (ET) on Thursday, July 14, 2016 DURHAM, N.C. — Scientists at Duke Health are part of a team that has discovered a type of cell surrounding blood vessels can also serve as a starting point for sarcoma, a Read more about Benjamin Alman, M.D., and Team Trace Origin Cell of Bone and Soft Tissue Tumors, Test Drug Target[…]
TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes. This Read more about ScarX Therapeutics closes $2 million Series A financing[…]
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in Read more about Gene mutation drives cartilage tumor formation[…]
Why do vampires from Dracula to Angel seem to crave the blood of the young and beautiful? The undead may be onto something. Young blood, it seems, has special healing properties that have been lost in older blood. A recent finding by scientists from the Hospital for Sick Children, Toronto, and Duke University challenges long-held ideas about Read more about Vampire Healing: Young Blood Can Mend Old Broken Bones[…]